Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 3381-3390 of 10954

Edit search filters
  1. KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD-19 CAR T) Therapy, in Subject With Treatment Refractory Stiff Person Syndrome

    Rochester, MN

  2. Impact Of RFA On Esophageal Distensibility And Mucosal Impedance

    Rochester, MN

  3. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  4. Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR

    Rochester, MN

  5. A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP)

    Scottsdale/Phoenix, AZ

  6. Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

    Rochester, MN

  7. A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia

    Rochester, MN

  8. Combination Therapies with Adagrasib in Patients with Advanced NSCLC With KRAS G12C Mutation

    Jacksonville, FL, Rochester, MN

  9. CNS Tumors With Latent Residual Disease To Guide Individualized Therapies

    Rochester, MN

  10. Lu AF82422 in participants with Multiple System Atrophy

    Rochester, MN

.

Mayo Clinic Footer